Forxiga will become a basic treatment for chronic kidney dz

SGLT-2 inhibitor added chronic kidney disease, demonstrating kidney protection effect

Diabetes → Heart failure → Unlimited expansion of kidney failure

Complement with existing drugs

"SGLT-2 inhibitors are no longer diabetes drugs.

 

It will be recognized by doctors of kidney medicine as a basic medicine that protects kidney function and is good for use with other medicines." Physicians expect SGLT-2 inhibitors, which have expanded their scope to kidney treatments.

 

Choi Bum-soon, a professor of kidney medicine at the University of Catholic Medicine at Eunpyeong St.

 

Mother's Hospital, commented on the new treatment option "Forxiga (Dapagliflozin)" that appeared in more than 20 years at an online press conference.

 

From the left, Professor Ko Kang-ji of Korea University Guro Hospital, Professor Yang Chul-woo of Seoul St.

 

Mary

AstraZeneca's Forxiga was the first SGLT-2 inhibitor to obtain kidney medication.

 

Forxiga, which began with diabetes drugs, was foreseen through several studies.

 

Forxiga showed decreased cardiovascular events, kidney protection benefits, and decreased albuminuria in the DECLARE-TIMI 58 study of diabetics.

 

The subsequent DAPA-CKD study demonstrated excellent kidney protection in patients with chronic kidney disease with a tetrahedron filtration rate of 25 to 75μg/min/1.73㎡, regardless of type 2 diabetes.

 

"There have been few drugs to help patients not to deteriorate their kidney function," said Koh Kang-ji, a professor of kidney medicine at Korea University's Guro Medical School, at a meeting on the 30th to commemorate the addition of Forxiga chronic kidney disease.

 

"The RAAS blocker worked, but it was 20 years ago that Forxiga was very welcome, and because it effectively reduces the pressure in the glomerulus as a different mechanism than the RAAS blocker, it can be used complementively." Professor Ko emphasized Forxiga's role in early patient treatment.

 

"If we use Forxiga in early patients, we can effectively reduce chronic progression by increasing eGFR and we can use it effectively and safely," he said.

 

"We need to make various efforts to increase the diagnosis rate of mild patients and quickly apply Forxiga." Choi gave advice on the proper use of drugs through Forxiga.

 

The DAPA-CKD study found that the Forxiga administration group had a lower eGFR than the control group at the beginning.

 

Professor Choi said, "Because the graph crossover over time, it is important for the medical team to confidently talk about patients' anxiety." "A 10% decrease compared to the baseline is a temporary phenomenon, and if more than 30% changes, we choose to temporarily stop and rewrite medicine." He added, "Since using Forxiga may cause dehydration, it is recommended to be careful of use in elderly people and patients scheduled for endoscopy and surgery the next day, and urinary tract infections are not worth worrying about." In its revised guidelines for treating heart failure announced this month, the ESC recommended SGLT-2 inhibitors such as Forxiga and Jardiance as primary treatments for patients with HFrEF.

 

As Jardiance demonstrated its effectiveness in cardiac output coefficient-preserving heart failure (HFpEF) patients, the scalability of SGLT-2 inhibitors was further broadened.

 

The medical team predicted that SGLT-2 inhibitors will become a major treatment option even in kidney disease.

 

Yang Chul-woo, professor of kidney medicine at Catholic University's Seoul St.

 

Mary's Hospital, said, "In order to live a long life as a joke, anti-hypertensive drugs such as Aspirin, Statins, and RAAS are essential, and the fourth drug is Forxiga (SGLT-2 inhibitor)." "We believe that SGLT-2 inhibitors will become a basic drug, and Forxiga is playing an important role as a leader," he said.